APA (7th ed.) Citation

GG, E., AJ, L., Z, A., L, K., JA, E., S, W., . . . MM, T. (2026). Microbiome-Targeted Antibiotics Provide No Additional Microbiologic or Inflammatory Benefit during Cystic Fibrosis Pulmonary Exacerbations: Results from the CFMATTERS Trial. American journal of respiratory and critical care medicine. https://doi.org/10.1093/ajrccm/aamag336

Chicago Style (17th ed.) Citation

GG, Einarsson, et al. "Microbiome-Targeted Antibiotics Provide No Additional Microbiologic or Inflammatory Benefit During Cystic Fibrosis Pulmonary Exacerbations: Results from the CFMATTERS Trial." American Journal of Respiratory and Critical Care Medicine 2026. https://doi.org/10.1093/ajrccm/aamag336.

MLA (9th ed.) Citation

GG, Einarsson, et al. "Microbiome-Targeted Antibiotics Provide No Additional Microbiologic or Inflammatory Benefit During Cystic Fibrosis Pulmonary Exacerbations: Results from the CFMATTERS Trial." American Journal of Respiratory and Critical Care Medicine, 2026, https://doi.org/10.1093/ajrccm/aamag336.